This General Practice is research active
Conducting high-quality clinical research helps us to keep improving NHS care by finding out which treatments work best.
In this practice, you might be asked to take part in a clinical research study. Alternatively, ask our staff about clinical studies suitable for you.
Taking part in a clinical research study is voluntary and can be a rewarding experience.
To find local clinical research studies, go to: www.ukctg.nihr.ac.uk
This practice is part of the NIHR Clinical Research Network – Primary Care. This is the research division of the NHS and is funded by the Department of Health.
The aim of this network is to provide the evidence to enable patients to receive the best possible care. Doctors at the practice may contact you from time to time when you are potentially eligible for a research study. Whether or not you take part in any research study is entirely up to you. The decision that you take will not affect your care in this practice in any way. The information that you give to research study will always remain confidential.
- Are you over 35?
- Are you seeing the doctor today because you have chest or bowel symptoms?
- Would you be interested in taking part in a research study?
Your Practice is taking part in a research study to try and improve the early diagnosis of lung and bowel cancer, and to better identify people who are unlikely to have the disease.
The study is being led by Professor Paul Little at the University of Southampton, and supported by the Universities of Birmingham, Bristol, Keele, University College London, Manchester, Nottingham and Oxford. It has NHS Ethical Committee approval.
People who agree to take part will be asked for a slightly longer than usual medical history.
They will also be invited to provide a blood sample and to complete a lifestyle questionnaire at home (ideally online).
The lifestyle questionnaire will ask about diet, smoking, and attitudes to doctors and life in general. It will also ask about symptoms – these questions might be about lung problems e.g. coughs, or bowel problems e.g. changes in bowel habit.
If you think you might like to help, please tell your doctor.
Your doctor may also ask you if you would like to help. When doctors and researchers try to understand more, we often ask thousands of people to share information with us to identify factors that might have an impact on the development of disease. That’s why at this surgery we’re inviting patients who have chest or bowel symptoms of any kind to take part in the CANDID study. Being asked to take part does not mean anybody thinks you have a serious illness or cancer, only that you have some of the symptoms we are looking at.
You do not have to help. It is your choice to take part or not. You can also change your mind after you have said yes.
Please feel free to ask the doctor any questions you may have.
CANDID is an observational cohort study. It aims to identify which symptoms and examination findings are most effective in predicting lung and colorectal cancer.
MIR is a randomised, double-blind, placebo-controlled trial, which will examine the effectiveness of mirtazapine given in addition to SSRI or SNRI antidepressants for patients with TRD in primary care.
Patients who have been diagnosed with depression and who have taken antidepressants for at least 6 weeks but who continue to have significant symptoms will be eligible to take part. If you agree to collaborate, we would need your help in identifying potential participants. Those patients who agree to be contacted by the research team, and who are eligible and give informed consent, will be randomised into one of the two groups: (1) mirtazapine plus usual SSRI/SNRI or (2) placebo plus usual SSRI/SNRI.
People who have severe mental illnesses (SMI) are at higher risk of developing cardiovascular disease (CVD). The PRIMROSE trial will assess an intervention to address this risk.
The PRIMROSE service will support patients to lower their cholesterol and other risk factors by identifying and monitoring patient-led goals to improve cardiovascular health e.g. taking medication, stopping smoking, improving diet, increasing physical activity or reducing drinking.
We want to compare the experiences of people in practices which deliver the service with those who receive usual care over a period of 1 year.
HEAT (Helicobacter Eradication Aspirin Trial) is a large scale outcomes study designed to see whether Helicobacter pylori eradication reduces the incidence of ulcer bleeding in aspirin users. This trial is being run by the University of Birmingham and is funded by the National Institute of Health Research (NIHR).